Participated · Equity · Nov 2025

Founded in 2020, Iambic Therapeutics integrates pioneering AI models, such as its Enchant multimodal transformer and NeuralPLexer structure predictor, with automated chemistry to run weekly design-make-test cycles. The platform is used to generate differentiated development candidates and has already delivered new drugs into human trials with what the company claims is unprecedented speed. Its lead asset, IAM1363, has shown anti-tumor activity and a favorable safety profile in HER2-wild-type and HER2-mutated cancers, and is now part of a clinical collaboration with Jazz Pharmaceuticals. Additional internal programs targeting KIF18A and CDK2/4 are expected to enter the clinic soon. Iambic is also engaged in a technology-enablement collaboration with Revolution Medicines that pairs proprietary data with NeuralPLexer capabilities. The company advances both wholly owned and partnered pipelines aimed at addressing urgent unmet needs. Backed by a recent oversubscribed financing of more than $100 million, Iambic is positioned to expand its pipeline, partnerships, and platform innovations.

Participated · Series B · Mar 2023

ArriVent Biopharma focuses on accelerating the global development of innovative biopharmaceutical products with an initial focus in oncology. Its lead product candidate, furmonertinib, is a highly brain-penetrant, mutant-specific EGFR kinase inhibitor. The company uses a deep and global network to access drug candidates at various development stages, including those from China and other emerging biotech hubs. ArriVent pursues strategic collaborations to globalize medicines for patients with unmet medical need across a broad range of diseases. Following a $155M Series B, the company intends to use proceeds to support pivotal Phase 3 and additional studies of furmonertinib and to fund future pipeline expansion. The company is led by CEO Bing Yao and added board appointees in conjunction with the financing. ArriVent Biopharma identifies therapeutics developed in China and other emerging biotech hubs and in-licenses ex-China rights to develop them for U.S., EU and other markets. Its current pipeline anchor is furmonertinib, an EGFR TKI recently approved in China for NSCLC, which ArriVent secured ex-China rights to from Allist Pharma. The company plans to submit an IND this year to study furmonertinib in EGFR-mutant NSCLC patients in the U.S. ArriVent aims to repeat the furmonertinib blueprint by seeking additional validated assets to expand its pipeline. Leadership includes CEO Bing Yao and co-founder/chief medical officer Stuart Lutzker, who will work to gather the clinical data needed for Western development. Financially, ArriVent has secured up to $150 million to fund these activities, including $90 million upfront and up to $60 million contingent on milestones.

Participated · Series A · Feb 2022

Walking Fish Therapeutics develops engineered B cell medicines and a platform for protein factories and oncology applications. The company has expanded its pipeline to target oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production. Since debuting in September 2021, its platform has demonstrated positive preclinical data across multiple indications. Walking Fish says recent innovations in B cell engineering and manufacturing enabled the pipeline expansion and new product opportunities. The company plans to use the new financing to accelerate platform development and further establish leadership in B cell therapeutics. Leadership includes Co-Founder and CEO Dr. Lewis “Rusty” Williams.

Participated · Equity · Jan 2022

Maze Therapeutics is a clinical-stage biopharmaceutical company that uses human genetics and its Compass platform to develop novel small-molecule precision medicines for renal, cardiovascular and related metabolic diseases. Its pipeline is led by two wholly owned lead programs, MZE829 (an oral APOL1 inhibitor) and MZE782 (an oral SCL6A19 inhibitor). MZE829 is being evaluated for APOL1 kidney disease, including focal segmental glomerulosclerosis (FSGS), with a Phase 2 trial expected to begin by Q1 2025. MZE782 is in a Phase 1 healthy volunteer trial with plans to evaluate it for chronic kidney disease (CKD) and phenylketonuria (PKU); Phase 1 data are expected in the second half of 2025. The company announced an oversubscribed $115 million Series D financing (which included conversion of issued convertible notes previously purchased by existing investors) to support advancement of these clinical programs and future pipeline work. Maze is based in South San Francisco, Calif., and intends to use the financing to optimize its upcoming Phase 2 trial and further explore the potential of both lead programs. Maze Therapeutics applies advanced data science, human genetics and functional genomics via its Maze Compass platform to discover small-molecule and biologic therapies for genetically defined disorders. The company has generated nine programs and two joint ventures since its 2019 launch and is advancing programs across rare and common genetically defined diseases. Its most advanced programs include MZE001 for Pompe disease, an APOL1 program for chronic kidney disease, and an ATXN2 program for amyotrophic lateral sclerosis (ALS). MZE001 is expected to enter the clinic in the first half of 2022 as the company transitions to clinical-stage development. Maze intends to use its platform and the recent financing to expand variant functionalization and accelerate end-to-end computational chemistry–informed drug discovery. The company is based in South San Francisco. Maze Therapeutics was launched to translate human genetic insights—specifically genetic modifiers—into novel therapeutics. The company aims to expand understanding of natural disease protection provided by genetic modifiers by combining global studies of human genetic variation with large-scale gene perturbation experiments. Maze plans to use those integrated insights to create medicines built around protective modifier genes to treat multiple diseases. The company announced an initial investment commitment of $191 million to support its launch and R&D activities. Maze has assembled a team of prominent scientific founders and senior leaders to drive discovery and drug development.

Participated · Series B · Oct 2021

Structure Therapeutics, formerly ShouTi, is a clinical-stage global biopharmaceutical company that leverages structural biology and computational design to discover next-generation small-molecule therapies focused on GPCR targets. Its lead program, GSBR-1290, is an orally available small-molecule GLP‑1 receptor agonist being developed for type 2 diabetes mellitus and obesity. The company completed dosing in a single ascending dose Phase 1 study of GSBR-1290 in 48 healthy volunteers to evaluate safety, tolerability and pharmacokinetics; no serious adverse events were reported. Structure Therapeutics designs biased GLP‑1R agonists intended to mitigate β‑arrestin–mediated internalization and desensitization and to offer a differentiated oral alternative to peptide biologics. Proceeds from the recent financing will be used to advance the lead programs through clinical investigation and to expand application of its structure-based drug discovery platform across GPCR targets. The company announced a corporate name change to Structure Therapeutics to reflect its foundation in structural biology and computational design. ShouTi combines state-of-the-art computational chemistry, structural biology, and large-scale data integration to design orally available medicines with improved pharmaceutical properties. The platform focuses on high-resolution membrane protein structures, particularly GPCRs, to convert biologics and peptide therapeutics into small molecules with enhanced bioavailability and stability. ShouTi is advancing a clinical-stage pipeline targeting chronic cardiovascular, metabolic, and pulmonary diseases. Proceeds from its recent financing will be used to advance the discovery platform and continue development of the clinical-stage programs. The leadership team includes experienced drug developers and pioneers in high-throughput structure-based drug discovery, led by CEO Raymond Stevens. With the Series B, ShouTi has raised $158 million since initiating operations.